Previous 10 | Next 10 |
enVVeno Medical press release ( NASDAQ: NVNO ): Q3 Net Loss of $6.1M The company ended the quarter with $42.7 million in cash and cash equivalents, and investments. The company's burn rate for the third quarter was $4.5 million, in line with previous guidance of $4.0 -...
- Ended the quarter with $42.7 million in cash and investments - Burn rate of $4.5 million for the quarter - Runway extends through the end of 2024 including release of SAVVE topline pivotal trial data and initiation of TAVVE first in human study IRVINE, CA / ACCESSWIRE / Octob...
The following slide deck was published by enVVeno Medical Corporation in conjunction with this event. For further details see: enVVeno Medical (NVNO) Investor Presentation - Slideshow
Summary enVVeno Medical continues to advance its key product pipeline through two clinical trials. The company's procedures could potentially provide a remedial breakthrough for treatment of chronic venous insufficiency. The two latest clinical trials have garnered investor's ...
Live video webcast fireside chat on Thursday, September 29 th at 2:00 PM ET IRVINE, CA / ACCESSWIRE / September 22, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced ...
Potential relief to approximately 3.5 million CVI sufferers Designed to be used by an expansive network of physicians Initial bench testing and animal testing successfully completed Awaiting regulatory approval to begin first-in-human testing, which is expected by end of 2022...
- Conference call with live audio webcast to be held on Wednesday, September 21 st at 4:30 PM ET IRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous di...
IRVINE, CA / ACCESSWIRE / September 12, 2022 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, CEO of enVVeno, will present at the H.C. Wainwright 24th An...
IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belt...
enVVeno Medical press release ( NASDAQ: NVNO ): Q2 Net Loss of $7.1M The company's burn rate for the second quarter was $4.0 million, in line with previous guidance of $4.0 - $5.0 million expected cash burn per quarter. Quarter end cash and cash equivalents, and invest...
News, Short Squeeze, Breakout and More Instantly...
enVVeno Medical Corp Com Company Name:
NVNO Stock Symbol:
NASDAQ Market:
enVVeno Medical Corp Com Website:
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27 th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatmen...
91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to Veno...
IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be ...